CSPC Pharmaceutical Group (1093) AI Stock Analysis

• Market Cap: HK$111.70B
• Dividend Yield: 2.7%
• Average Volume (3M): 135.86M
• Price to Earnings (P/E): 22.9
• Beta (1Y): 0.83
• Revenue Growth: -18.07%
• EPS Growth: -33.27%
• Country: HK
• Employees: 21,400
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.04
• Shares Outstanding: 11,522,452,000
• 10 Day Avg. Volume: 105,139,995
• 30 Day Avg. Volume: 135,859,703
• PEG Ratio: -0.53
• Price to Book (P/B): 1.63
• Price to Sales (P/S): 1.90
• P/FCF Ratio: 30.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$11.28
• Price Target Upside: 16.22% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): 0.67
• Revenue Forecast (FY): HK$31.93B

• Rating: 74 Outperform
• Price Target: HK$11.00 ▲(13.29% Upside)
• Action: Reiterated Date: 02/04/26
• Date: Action: Reiterated 02/04/26

The score is driven primarily by strong financial performance (profitability, growth, and low leverage), supported by a constructive technical setup with price above key moving averages. Valuation is the main constraint, with a relatively high P/E only partly offset by the dividend yield.

Positive Factors

Very low leverage / strong balance sheet

Extremely low debt-to-equity (~0.02) and a high equity ratio provide durable financial flexibility. This reduces solvency risk, supports continued R&D and capex funding, and gives the company resilience to industry cycles and policy changes over the coming months.

Negative Factors

Volatile operating cash flow and capex

Variability in operating cash flow and capex creates uncertainty in free cash flow timing. For a drug developer, unpredictable cash generation can complicate steady funding of clinical programs, M&A or capacity expansion and may force episodic financing.

CSPC Pharmaceutical Group Business Overview & Revenue Model

Company Description

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internati...

Read more

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internati...

How the Company Makes Money

CSPC Pharmaceutical Group generates revenue primarily through the sale of its pharmaceutical products, which include prescription medications and over-the-counter drugs. The company has a robust revenue model that includes direct sales to hospital...

Read more

CSPC Pharmaceutical Group generates revenue primarily through the sale of its pharmaceutical products, which include prescription medications and over-the-counter drugs. The company has a robust revenue model that includes direct sales to hospital...

CSPC Pharmaceutical Group Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	27.22B	29.54B	31.47B	31.59B	27.41B	23.58B
Gross Profit	18.16B	20.67B	22.19B	22.73B	20.79B	17.67B
EBITDA	6.72B	7.18B	8.59B	8.85B	7.57B	6.80B
Net Income	4.07B	4.41B	5.88B	6.22B	5.51B	4.88B
Balance Sheet
Total Assets	46.00B	47.23B	50.92B	41.77B	42.50B	35.65B
Cash, Cash Equivalents and Short-Term Investments	10.63B	8.25B	13.09B	13.87B	13.87B	10.47B
Total Debt	495.00M	507.33M	706.90M	659.28M	115.04M	523.95M
Total Liabilities	11.14B	11.20B	11.26B	11.07B	9.37B	7.96B
Stockholders Equity	33.25B	34.33B	36.53B	29.77B	31.79B	26.48B
Cash Flow
Free Cash Flow	1.48B	1.86B	2.29B	6.62B	4.15B	5.91B
Operating Cash Flow	6.86B	4.53B	4.18B	9.23B	5.86B	7.67B
Investing Cash Flow	-4.66B	-3.86B	607.27M	-6.80B	-637.33M	-2.60B
Financing Cash Flow	-3.32B	-5.25B	-2.30B	-1.90B	-2.20B	-1.65B

CSPC Pharmaceutical Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1093, the sentiment is Positive. The current price of 9.71 is above the 20-day moving average (MA) of 8.97, above the 50-day MA of 9.51, and above the 200-day MA of 9.00, indicating a bullish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 57.60 is Neutral, neither overbought nor oversold. The STOCH value of 85.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1093.

CSPC Pharmaceutical Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1093	74 Outperform	HK$111.70B	22.87	11.30%	2.70%	-18.07%	-33.27%
2607	67 Neutral	HK$65.87B	6.62	7.64%	2.67%	2.77%	39.24%
0867	63 Neutral	HK$34.96B	19.33	8.60%	2.26%	11.78%	19.06%
1177	61 Neutral	HK$113.21B	43.78	11.85%	1.40%	13.69%	50.71%
3320	61 Neutral	HK$39.39B	6.37	7.91%	2.95%	―	―
0874	59 Neutral	HK$40.60B	8.90	7.89%	7.15%	1.13%	-13.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

CSPC Pharmaceutical Group Corporate Events